Embrace disclosure, or kiss something else goodbye?
This article was originally published in Scrip
Executive Summary
Let's be clear: this is not a UK-only issue. However, the debate over clinical trial data disclosure has come to the boil this week in the UK, fuelled by the concentrated heat generated from the publication of Bad Pharma by Ben Goldacre, a book which levels criticism at the industry, regulators, doctors and academics for a wide range of issues including drug marketing practices, conflicts of interest and, to a large extent, data disclosure.